Skip to main content

AbbVie — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

57
Companies
$2.6B
Total invested
$48.6M
Avg. check
17
Industries
Biotechnology 21Health Care 11Therapeutics 11Medical 10Biopharma 4Medical Device 4+11 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 57
Carisma Therapeutics
September 2022

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

Biotechnology · Philadelphia$30.0M Series C
Oisin Biotechnologies
August 2025

Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases.

Biopharma · Seattle$10.0M Series A
Stemson Therapeutics
July 2021

Stemson Therapeutics is a pre-clinical stage cell therapy company.

Biotechnology · San Diego$15.0M Series A
Caribou Biosciences
July 2023

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Biotechnology · Berkeley$125.0M Post-IPO Equity
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
Inventiva Pharma
June 2026

Inventiva Pharma is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

Biopharma · Daix$120.0M Post-IPO Equity
Morphic Therapeutic
May 2023

Morphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.

Biotechnology · Waltham$276.0M Post-IPO Equity
Quanta Therapeutics
May 2023

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes.

Biotechnology · San Francisco$50.7M Series D
Endlyz Therapeutics
April 2026

Endlyz Therapeutics is developing disease-modifying therapeutics for Parkinson’s disease (PD) and other dementias.

Biotechnology · Boston$17.3M Seed
ThirtyFiveBio
April 2025

ThirtyFiveBio is a biotech company developing a gut epithelial shield for patients with colitis

Biotechnology · AbingdonVenture - Series Unknown
Capsida Biotherapeutics
February 2023

Capsida Biotherapeutics is a biotechnology company that specializes in tackling monogenetic and sporadic CNS and non-CNS disorders.

Biotechnology · Newbury ParkCorporate Round
Syndeio Biosciences
May 2025

Syndeio Biosciences is a newly launched biotech company pioneering precision neurotherapeutics.

Biotechnology · Indianapolis$90.0M Venture - Series Unknown
Starday Foods
April 2025

Starday Foods is a healthy and sustainable food products company.

Consumer · New City$8.0M Series A
AmbAgon Therapeutics
February 2025

AmbAgon Therapeutics is a developer of cancer molecule therapeutics.

Biotechnology · San Francisco$5.0M Venture - Series Unknown
Cephagenix
January 2025

Cephagenix focuses on identifying and developing new, effective migraine therapies.

Health Care · Glostrup$9.3M Seed
Accent Therapeutics
January 2024

Accent Therapeutics is a biopharmaceutical company.

Biotechnology · Lexington$75.0M Series C
Light Horse Therapeutics
January 2025

Light Horse Therapeutics is a small molecule drug discovery, pioneering to target that causes disabling and life-threatening diseases.

Biotechnology · San Diego$62.0M Series A
Effector Therapeutics
January 2024

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Biotechnology · San Diego$15.0M Post-IPO Equity
Ribon Therapeutics
December 2022

Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.

Biotechnology · Cambridge$25.0M Venture - Series Unknown
DISCO Pharmaceuticals
December 2025

DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.

Manufacturing · Cologne$42.3M Seed
Soufflé Therapeutics
January 2025

Soufflé Therapeutics has potent, precise, and safe medicines can be designed and developed for all diseases.

Biopharma · Watertown$200.0M Series A
Nitrase Therapeutics
November 2021

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Biotechnology · Jackson$7.0M Series A
Artios Pharma
November 2025

Artios Pharma is a biopharmaceutical company that provides new solutions in the DNA damage response (DDR) field.

Biopharma · Cambridge$115.0M Series D
Jnana Therapeutics
November 2022

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Biotechnology · Boston$107.0M Series C

Where AbbVie invests

Biotechnology21
Health Care11
Therapeutics11
Medical10
Biopharma4
Medical Device4

About AbbVie's portfolio

How many companies has AbbVie invested in?▸

AbbVie has invested in 57 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does AbbVie invest in?▸

AbbVie's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Biopharma. The firm invests across 17 different industry categories.

What is AbbVie's largest investment?▸

Among tracked funding rounds, Morphic Therapeutic received $276.0M in a Post-IPO Equity round. AbbVie's total known invested capital is $2.6B.

What is the average investment size for AbbVie?▸

AbbVie's average investment size is $48.6M across its portfolio of 57 companies.

What are AbbVie's most recent investments?▸

Recent AbbVie portfolio additions include Carisma Therapeutics, Oisin Biotechnologies, Stemson Therapeutics, Caribou Biosciences, Mozart Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 57 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →